Quest Diagnostics Inc. - DGX STOCK NEWS

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has announced a quarterly cash dividend of $0.75 per share. The dividend will be payable on October 21, 2024 to shareholders of record as of October 4, 2024. This announcement demonstrates Quest Diagnostics' commitment to returning value to its shareholders and reflects the company's financial stability and confidence in its future prospects.

A Quest Diagnostics study published in the Journal of Lower Genital Tract Disease reveals significant gaps in STI testing for pregnant women. Analyzing over 4 million pregnancies, researchers found that 4% of women tested positive for chlamydia or gonorrhea in the first trimester. Alarmingly, 35% of these women didn't receive a follow-up negative test before delivery, suggesting potential untreated infections. The study highlights inconsistencies in guideline-based care, with 2% of initially negative patients later testing positive during pregnancy. Researchers recommend improving adherence to existing guidelines and updating recommendations for STI testing to enhance maternal and newborn health outcomes.

Quest Diagnostics celebrated National Logistics Day on June 28th, honoring their logistics professionals who ensure specimen delivery to labs nationwide. The PR highlights Jamie Croft's 13-year journey with Quest, from stat driver to Advanced RSR. Jamie's story showcases Quest's commitment to employee growth and development within the healthcare industry.

Initially aspiring to roles like dental hygienist or nurse, Jamie found her calling in Quest's logistics team. She progressed from weekend route driver to stat position, learning various aspects of logistics operations. Jamie's experience underscores Quest's role in providing career opportunities and fostering a supportive work environment in the medical field.

Quest Diagnostics (NYSE:DGX) has been named to the 2024 Disability Equality Index® Best Places to Work for Disability Inclusion for the seventh consecutive year. The company achieved a top score of 100, improving from 90 in the previous two years. This recognition comes from Disability:IN and the American Association of People with Disabilities (AAPD).

Quest's commitment to disability inclusion is demonstrated through its DiverseAbilities Employee Business Network (EBN), which has over 350 members and focuses on supporting organizations that assist people with disabilities. The company's efforts in creating a diverse, equitable, inclusive, and accessible workplace for its nearly 50,000 employees have been highlighted as key factors in achieving this recognition.

The Disability Equality Index, now in its 10th year, is considered the most comprehensive disability inclusion assessment tool in business, measuring various aspects including culture, leadership, employment practices, and community engagement.

Quest Diagnostics (NYSE: DGX) has been named to the 2024 Disability Equality Index® Best Places to Work for Disability Inclusion for the seventh consecutive year, achieving a top score of 100. This recognition, awarded by Disability: IN and the American Association of People with Disabilities (AAPD), highlights Quest's commitment to creating a diverse, equitable, inclusive, and accessible workplace.

Quest's success is attributed to initiatives like the DiverseAbilities Employee Business Network (EBN), which supports organizations aiding people with disabilities through employee giving campaigns and community outreach. The company's focus on disability inclusion is seen as vital to its performance, benefiting both employees and customers.

The Disability Equality Index, now in its 10th year, is recognized as the most comprehensive disability inclusion assessment tool in business, measuring various aspects including culture, leadership, access, employment practices, community engagement, and supplier diversity.

Quest Diagnostics celebrated National Logistics Day on June 28th, honoring their logistics professionals who ensure specimen delivery to labs nationwide. The PR highlights Carol Ann Mandichak's journey with Quest since October 2018, starting as a Route Service Representative (RSR) in the STAT position. Carol's career progression led her to become a Specialty RSR, training 17 new STAT RSRs and focusing on customer service excellence.

Carol emphasizes the importance of thorough specimen handling, ensuring correct temperature and never missing pickups. Her personal mantra, 'there is always a way,' aligns with the Quest Way, guiding her daily work. The story underscores Quest's commitment to creating a healthier world through dedicated logistics professionals who treat each specimen as a representation of a patient's life.

Bread of Life Academy, a Quest for Health Equity (Q4HE) grantee, celebrated the graduation of 40 students pursuing careers as phlebotomists and community health workers (CHWs). The academy, part of Bread of Life Inc.'s Healthy Houston Collective, aims to address healthcare disparities in underserved communities. Supported by the Quest Diagnostics Foundation, the program focuses on training individuals from marginalized backgrounds to fill critical shortages in allied health professions.

Dr. Morgan Rasmus Alfred, VP of Education, highlighted the unprecedented demand for allied health jobs in Texas and the graduates' role in bridging healthcare gaps. The Quest Diagnostics Foundation's grant has helped launch the Collective in 2022, aiming to improve healthcare access for over 9,000 people in Houston and Harris County.

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has announced a research collaboration with Dr. Simon Turcotte at the CRCHUM to evaluate treatment effectiveness in metastatic colorectal cancer (mCRC) patients. The study, named eDetect, will use Haystack MRD™ technology to assess circulating tumor DNA (ctDNA) as an early biological marker of treatment response and disease recurrence.

The collaboration aims to leverage Haystack MRD's exceptional sensitivity in detecting ctDNA to measure treatment response in oligometastatic CRC patients. This research could potentially guide future therapy decisions and improve patient care for mCRC, which is the second leading cause of cancer death in Canada and the United States.

BD (NYSE: BDX) and Quest Diagnostics (NYSE: DGX) have announced a global collaboration agreement to develop, manufacture, and commercialize flow cytometry-based companion diagnostics (CDx) for cancer and other diseases. This partnership aims to provide the pharmaceutical industry with an end-to-end solution for CDx development, ranging from exploratory panel development to FDA-approved diagnostic kit distribution.

The collaboration leverages BD's expertise in flow cytometry and Quest's proficiency in biomarker and assay development. Flow cytometry, an established laboratory technology, can rapidly analyze individual cells, potentially improving patient management and clinical outcomes. This initiative is expected to advance personalized medicine and potentially reduce healthcare costs by enabling more precise treatment selection.